KTX-120

KTX-120 is a novel IRAKIMiD development candidate, a heterobifunctional small molecule designed to induce the selective degradation of both Interleukin-1 receptor-associated kinase 4 (IRAK4) and the immunomodulatory drug (IMiD) substrates Ikaros (IKZF1) and Aiolos (IKZF3). Developed by Kymera Therapeutics, KTX-120 utilizes an IMiD-based cereblon binder to co-opt the ubiquitin-proteasome system for targeted protein degradation. This dual-targeting approach is intended to provide synergistic antitumor activity in MYD88-mutant B-cell malignancies, such as diffuse large B-cell lymphoma (DLBCL), by addressing both the myddosome signaling pathway and essential transcription factors. Preclinical studies have shown that KTX-120 induces rapid cell death and significant tumor regressions in MYD88-mutant cell-derived and patient-derived xenograft models, with the potential for intermittent oral or intravenous dosing.

Other names

IRAKIMiD